JP2006117697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006117697A5 JP2006117697A5 JP2006002633A JP2006002633A JP2006117697A5 JP 2006117697 A5 JP2006117697 A5 JP 2006117697A5 JP 2006002633 A JP2006002633 A JP 2006002633A JP 2006002633 A JP2006002633 A JP 2006002633A JP 2006117697 A5 JP2006117697 A5 JP 2006117697A5
- Authority
- JP
- Japan
- Prior art keywords
- leu
- peptide
- amino acids
- peptide according
- hydrophobic amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 150000001413 amino acids Chemical class 0.000 claims 17
- 230000002209 hydrophobic effect Effects 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN0589A AUPN058995A0 (en) | 1995-01-16 | 1995-01-16 | Novel peptide |
| AUPN0590A AUPN059095A0 (en) | 1995-01-16 | 1995-01-16 | Novel lipopeptide |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005034053A Division JP2005145985A (ja) | 1995-01-16 | 2005-02-10 | 新規ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006117697A JP2006117697A (ja) | 2006-05-11 |
| JP2006117697A5 true JP2006117697A5 (enExample) | 2006-11-09 |
| JP4522367B2 JP4522367B2 (ja) | 2010-08-11 |
Family
ID=25644844
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52191796A Expired - Fee Related JP3665342B2 (ja) | 1995-01-16 | 1996-01-16 | 新規ペプチド |
| JP2005034053A Pending JP2005145985A (ja) | 1995-01-16 | 2005-02-10 | 新規ペプチド |
| JP2006002633A Expired - Fee Related JP4522367B2 (ja) | 1995-01-16 | 2006-01-10 | 新規ペプチド |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52191796A Expired - Fee Related JP3665342B2 (ja) | 1995-01-16 | 1996-01-16 | 新規ペプチド |
| JP2005034053A Pending JP2005145985A (ja) | 1995-01-16 | 2005-02-10 | 新規ペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6057294A (enExample) |
| EP (1) | EP0804469B1 (enExample) |
| JP (3) | JP3665342B2 (enExample) |
| AU (1) | AU694602B2 (enExample) |
| CA (1) | CA2210812C (enExample) |
| DE (1) | DE69617396T2 (enExample) |
| ES (1) | ES2168456T3 (enExample) |
| WO (1) | WO1996022306A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057294A (en) * | 1995-01-16 | 2000-05-02 | Northern Sydney Area Health Service Of Pacific Highway | Peptide |
| EP0906339A2 (en) * | 1996-03-27 | 1999-04-07 | NG, Gordon, Y., K. | Receptor and transporter antagonists |
| US20050070478A1 (en) * | 1996-06-11 | 2005-03-31 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
| EP2009018A3 (en) | 1996-06-11 | 2009-03-18 | Northern Sydney and Central Coast Area Health Service | T cell antigen receptor peptides |
| US6696545B1 (en) | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| CN1216900C (zh) | 1997-04-11 | 2005-08-31 | 桑斯塔特医学有限公司 | 用于调节免疫系统活性和抑制炎症的细胞调节性亲脂肽 |
| US7026294B2 (en) * | 2000-05-19 | 2006-04-11 | University Of Maryland | Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes |
| AU2003210659A1 (en) | 2002-01-24 | 2003-09-02 | Sangstat Medical Corporation | Combination therapy for treatment of hiv infection |
| JP2008500289A (ja) * | 2004-05-27 | 2008-01-10 | ノヴォザイムズ グロペップ リミテッド | 炎症性気道疾患の治療 |
| AU2006293421A1 (en) * | 2005-09-22 | 2007-03-29 | Yeda Research And Development Co. Ltd., At The Weizmann Institute Of Science | Diastereomeric peptides for modulating T cell immunity |
| EP1870420A1 (en) | 2006-06-23 | 2007-12-26 | Max-Delbrück-Centrum Für Molekulare Medizin | Peptides regulating the surface expression of the T cell receptor |
| WO2010057275A1 (en) * | 2008-11-24 | 2010-05-27 | Sydney West Area Health Services | Cyclic peptides and uses thereof |
| US10138276B2 (en) | 2009-09-30 | 2018-11-27 | Signablok, Inc. | Inhibition of TCR signaling with peptide variants |
| US8513185B2 (en) * | 2009-10-13 | 2013-08-20 | Alexander B. Sigalov | Inhibition of TREM receptor signaling with peptide variants |
| EP3600357A4 (en) | 2017-03-31 | 2021-01-06 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING |
| WO2020036987A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888512A (en) * | 1987-01-30 | 1999-03-30 | Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte activity regulation by HLA peptides |
| CA2045578A1 (en) * | 1989-01-31 | 1990-08-01 | Megumi Kawai | Anaphylatoxin-receptor ligands |
| US5223485A (en) * | 1989-01-31 | 1993-06-29 | Abbott Laboratories | Anaphylatoxin-receptor ligands |
| HUT54896A (en) * | 1989-03-17 | 1991-04-29 | Chiron Corp | Process for producing aquous diagnosticum and vaccine of nanbv |
| AU8228791A (en) * | 1990-06-15 | 1992-01-07 | New York University | Heterohybridomas producing human monoclonal antibodies to hiv-1 |
| US5387671A (en) * | 1990-12-27 | 1995-02-07 | Abbott Laboratories | Hexa- and heptapeptide anaphylatoxin-receptor ligands |
| SG49008A1 (en) * | 1993-03-05 | 1998-05-18 | Cytel Corp | Hla-a2.1 binding peptides and their uses |
| ATE291230T1 (de) * | 1994-01-14 | 2005-04-15 | Matthias Dr Med Rath | Verwendung von methoden zur identifizierung von hydrophilen signal-oligopeptiden |
| US5709995A (en) * | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| AU2238395A (en) * | 1994-04-01 | 1995-10-23 | Immulogic Pharmaceutical Corporation | Haptenated peptides and uses thereof |
| US6057294A (en) * | 1995-01-16 | 2000-05-02 | Northern Sydney Area Health Service Of Pacific Highway | Peptide |
| US5753625A (en) * | 1995-05-12 | 1998-05-19 | Sangstat Medical Corporation | Treatment for inhibiting the progression of autoimmune disease |
-
1996
- 1996-01-16 US US08/875,013 patent/US6057294A/en not_active Expired - Fee Related
- 1996-01-16 ES ES96900472T patent/ES2168456T3/es not_active Expired - Lifetime
- 1996-01-16 CA CA002210812A patent/CA2210812C/en not_active Expired - Fee Related
- 1996-01-16 DE DE69617396T patent/DE69617396T2/de not_active Expired - Lifetime
- 1996-01-16 WO PCT/AU1996/000018 patent/WO1996022306A1/en not_active Ceased
- 1996-01-16 AU AU44272/96A patent/AU694602B2/en not_active Ceased
- 1996-01-16 EP EP96900472A patent/EP0804469B1/en not_active Expired - Lifetime
- 1996-01-16 JP JP52191796A patent/JP3665342B2/ja not_active Expired - Fee Related
-
2005
- 2005-02-10 JP JP2005034053A patent/JP2005145985A/ja active Pending
-
2006
- 2006-01-10 JP JP2006002633A patent/JP4522367B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020209285A5 (enExample) | ||
| JP2012525844A5 (enExample) | ||
| MX2007013031A (es) | Agentes terapeuticos de peptidos de toxina. | |
| JP2010519252A5 (enExample) | ||
| JP2013537907A5 (enExample) | ||
| JP2020002154A5 (enExample) | ||
| JP2018515101A5 (enExample) | ||
| JP2008541759A5 (enExample) | ||
| JP2008529500A5 (enExample) | ||
| JP2011502964A5 (enExample) | ||
| JP2013507439A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2017160222A5 (enExample) | ||
| TW200833840A (en) | Toxin peptide therapeutic agents | |
| JP2009537143A5 (enExample) | ||
| JP2011528332A5 (enExample) | ||
| MX2013011674A (es) | Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados. | |
| JP2011511753A5 (enExample) | ||
| JP2005516885A5 (enExample) | ||
| JP2014527040A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2015526391A5 (enExample) | ||
| JP2014532722A5 (enExample) | ||
| JP2014529399A5 (enExample) | ||
| JP2010513327A5 (enExample) |